Quality Control Growth MMQCI designs and manufactures quality control products for molecular diagnostics across inherited diseases, oncology, infectious diseases, and NGS panels, presenting cross-selling opportunities to labs expanding testing menus or adopting new panels.

Custom Solutions Their cGMP facility and openness to custom orders position MMQCI to partner with in vitro diagnostic manufacturers on tailored QC materials, enabling co-development deals with assay launches or platform integrations.

Recent Product Expansion Launched new controls such as eplex RP3 M530 and Birlinn CoV2-Flu-RSV M509, signaling a cadence of new offerings aligned with trending panels and pathogens, creating upsell and renewal opportunities for existing customers.

Mid Market Focus With 51-200 employees and revenue in the 10–25 million range, MMQCI operates in the mid-market segment, suggesting prioritization for targeted outreach to regional hospital labs, reference labs, and NI/OMICS service providers seeking scalable QC solutions.

Technology & Partnerships Leveraging cloud and software tools (Azure, Office 365, ERP like QuickBooks) alongside a diverse tech stack indicates readiness for digital-enabled sales processes, robustness for long-term support contracts, and potential for data-driven QC analytics collaborations.